Marc De Meulemeester

Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

Alexander So, Marc De Meulemeester, A. Pikhlak et al. · Arthritis & Rheumatism · 2010 · 308 citations

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

Naomi Schlesinger, Eduardo Mysler, Hsiao‐Yi Lin et al. · Annals of the Rheumatic Diseases · 2011 · 236 citations · Full text

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Naomi Schlesinger, Marc De Meulemeester, A. Pikhlak et al. · Arthritis Research & Therapy · 2011 · 133 citations · Full text

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Stéphane Heijmans, Marc De Meulemeester, Paul Reynders et al. · The Journal of Infectious Diseases · 2011 · 30 citations · Full text

Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study

Philippe van de Borne, André Peeters, Luc Janssens et al. · Acta cardiologica. Supplementum · 2022 · 18 citations · Full text